Accounting for the differences and understanding the appropriate way to model the marketplace for biosimilars, as opposed to generics, may have significant consequences for economic analyses in the context of litigation. In this article, we identify some of those differences and their implications.
Webinar Insights | The Rise of Competitive Rare Diseases: European Payer Perspectives
CRA recently hosted a webinar with leading European payer experts to discuss the increasingly competitive rare disease (RD) landscape